New data supports Hoya's DIMS lenses for myopic prevention among preschool-aged pediatrics
Research

New data supports Hoya's DIMS lenses for myopic prevention among preschool-aged pediatrics

Presented at ARVO, updated findings among the younger pre-myopics confirmed a protective effect of the patented and embedded technology on refractive status.
Hoya reports 8-year data on DIMS spectacle lenses for pediatric myopia
Research

Hoya reports 8-year data on DIMS spectacle lenses for pediatric myopia

Long-term study evaluated myopia control effect and user experience of patients wearing HOYA’s MiYOSMART spectacle lenses.
DIMS spectacle lenses may mitigate pediatric myopia
Research

DIMS spectacle lenses may mitigate pediatric myopia

Second-ever 6-year clinical trial of myopia control shows no rebound effects after cessation of treatment lens wear.
Breakthrough trial finds MiYOSMART iQ spectacle lenses halt childhood myopia progression
Research

Breakthrough trial finds MiYOSMART iQ spectacle lenses halt childhood myopia progression

Latest 12-month data details highest myopia-control efficacy results reported to date in myopes as young as age 4 wearing HOYA’s D.I.M.S. technology.
HOYA reports 6-month data on MiYOSMART iQ spectacle lenses for pediatric myopia
Research

HOYA reports 6-month data on MiYOSMART iQ spectacle lenses for pediatric myopia

Interim results find advanced lens and D.I.M.S. triple enhanced design tech to be twice as effective in controlling axial elongation and disease progression.
Hoya Vision launches spectacle lenses for pediatric myopia protection
Products

Hoya Vision launches spectacle lenses for pediatric myopia protection

The MiYOSMART photochromic and polarized spectacle lenses incorporate D.I.M.S. technology.
Researchers identify higher post-cataract TED risk in patients with thyroid disease
Research

Researchers identify higher post-cataract TED risk in patients with thyroid disease

Patients demonstrate up to 51% higher risk of developing TED in the year after surgery, with hyperthyroid patients facing more than double the risk.
Orasis adds free first fill, in-office dispensing for QLOSI
Products

Orasis adds free first fill, in-office dispensing for QLOSI

Two new access routes let ECPs start patients on prescription-based presbyopia drop, without routing through a direct-to-patient pathway.
Real-world data finds anti-VEGF use may not disrupt IZERVAY dosing patterns
Research

Real-world data finds anti-VEGF use may not disrupt IZERVAY dosing patterns

IRIS Registry study demonstrates similarities in safety and dosing intervals among patients undergoing concomitant anti-VEGF and IZERVAY therapy.
Aquatic virus linked to new human eye disease
Research

Aquatic virus linked to new human eye disease

Covert mortality nodavirus, a pathogen of farmed shrimp and fish, presented in the eye tissue of patients with a vision-threatening uveitis emerging in China.
NeuroVision expands retinal imaging-based neurodegenerative disease detection with new acquisition
Business

NeuroVision expands retinal imaging-based neurodegenerative disease detection with new acquisition

Retinal imaging developer adds Durin Life Sciences’ noninvasive, blood-based biomarker test to its integrated platform targeting cognitive diseases.
Real-world TED data finds disease advances beyond acute phase
Research

Real-world TED data finds disease advances beyond acute phase

Real-world study demonstrates heterogeneous disease progression in TED, challenging the traditional self-limited paradigm.
Marco Lombart named exclusive US distributor for Haag-Streit diagnostic technology
Products

Marco Lombart named exclusive US distributor for Haag-Streit diagnostic technology

Agreement extends to the Lenstar 900 optical biometer and Octopus 600 and 900 perimeter devices.
Could human breast milk treat dry eye disease?
Research

Could human breast milk treat dry eye disease?

Narrative review traces ophthalmic uses of human milk back to anciant Egyptian papyrus, finding the biology behind it might hold up.
Dry eye may indicate early signs of autoimmune disease
Research

Dry eye may indicate early signs of autoimmune disease

Study findings suggest ocular surface symptoms may precede systemic autoimmune diagnosis by several years.
Study: CV risk score identifies future eye disease risk
Research

Study: CV risk score identifies future eye disease risk

Pooled Cohort Equations (PCE) score may help identify high-risk patients when preventive measures may protect their vision.
Study correlates visual impairment with sleep disruptions
Research

Study correlates visual impairment with sleep disruptions

Poor sleep quality associated with a significantly higher risk of visual impairment, diabetic retinopathy, and other ocular conditions.
Samsung Bioepis and Regeneron settle EYLEA biosimilar US patent dispute
Legal

Samsung Bioepis and Regeneron settle EYLEA biosimilar US patent dispute

Settlement and license agreement clears the way for a January 2027 commercial launch of OPUVIZ 2 mg (aflibercept-yszy) injection.
Cannabis implicated in ocular inflammatory disease development
Research

Cannabis implicated in ocular inflammatory disease development

Cannabis use associated with higher risk of developing uveitis and other posterior segment diseases.
Novartis's ianalumab earns FDA Breakthrough Therapy designation for Sjögren’s disease
Pipeline

Novartis's ianalumab earns FDA Breakthrough Therapy designation for Sjögren’s disease

Fully human monoclonal antibody is delivered as a monthly subcutaneous injection; company plans to submit for global approval in early 2026.